Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Latency-reversing agents and combination regimens in virologically suppressed HIV-1 infection
ChiCTR2600131321Phase 2Not yet recruiting
- Sponsor
- Department of Infectious Diseases, Tangdu Hospital, The Fourth Military Medical University
- Start
- Dec 2025
- Modality
- Small Molecules, Cytokines & Interferons → Recombinant Proteins and Enzymes, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label trial of tucidinostat, metformin, peginterferon alfa-2b and entinostat in Human immunodeficiency virus infection type 1 (6 arms), sponsored by Department of Infectious Diseases, Tangdu Hospital, The Fourth Military Medical University. Primary endpoints: Plasma HIV-1 RNA load and Quantitative level of cell-associated HIV RNA. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
tucidinostatmetforminpeginterferon alfa-2bentinostat
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on ChiCTR2600131321.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600131321.